WOBURN, Mass.--(EON: Enhanced Online News)--Zindol® LLC, a subsidiary Aphios Corporation, announces plans to raise $10 million from high net worth investors, family offices, strategic corporate partners and institutional investors for the clinical development of Zindol® for the treatment of nausea in cancer patients undergoing chemotherapy.
“This randomized, placebo-controlled, double-blind clinical trial assessed the efficacy of Zindol in treating chemotherapy induced nausea in 576 cancer patients. All doses of Zindol significantly reduced acute nausea severity compared to the placebo. No significant adverse events were reported.”
Potential investors are encouraged to visit http://www.fundable.com/zindol-llc to read about the Company’s business plans and risks associated with this investment.
“Nausea has a significant impact on cancer patients undergoing chemotherapy,” says Dr. Trevor P. Castor, President and CEO. “Not being able to control persistent nausea can lead to malnutrition, which is commonplace among cancer patients. Untreated nausea-related malnutrition can lead to compromised immune functioning and general malaise. Not being able to eat affects quality of life. This unmet medical need of chemotherapy induced nausea and vomiting (CINV), especially nausea, is acute in the adult and pediatric populations, and is the reason why up to 50% of patients do not complete subsequent chemotherapy treatment.”
“A successful Phase II/III clinical trial on Zindol as an adjuvant to conventional 5-HT3 anti-emetics has been completed,” continues Dr. Castor. “This randomized, placebo-controlled, double-blind clinical trial assessed the efficacy of Zindol in treating chemotherapy induced nausea in 576 cancer patients. All doses of Zindol significantly reduced acute nausea severity compared to the placebo. No significant adverse events were reported.”
Zindol is being developed to improve the quality of life of cancer patients undergoing chemotherapy by reducing the incidence of nausea without clinically significant adverse effects. We plan to conduct a pivotal Phase III clinical trial on Zindol for the adjunctive treatment of nausea in adults undergoing chemotherapy, file a new drug application (NDA) with the FDA and then initiate a clinical program in a pediatric population.
Subsequently, Zindol will be clinically developed for post-operative nausea and vomiting, morning sickness, motion sickness and medication-related nausea and vomiting.
ABOUT ZINDOL LLC
Zindol, LLC, a limited liability Delaware Corporation, is a wholly-owned subsidiary of Aphios Corporation that is focused on developing Zindol for treating an unmet medical need of cancer patients undergoing chemotherapy.
ABOUT APHIOS CORPORATION
Aphios® Corporation (www.aphios.com), a Delaware C-corporation, is a clinical-stage biotechnology company, which is developing enabling technology platforms and enhanced therapeutics for chronic, debilitating diseases and improving quality of life of cancer and Alzheimer’s disease patients.